Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for the treatment of Alzheimer's disease. Headquartered in Newton, Massachusetts, the company's mission is to tackle Alzheimer's by targeting what it believes to be a key underlying cause: toxic soluble amyloid beta oligomers (AβOs).

The company's lead product candidate is sabirnetug (ACU193), a humanized monoclonal antibody designed to selectively target AβOs. Sabirnetug is currently being evaluated in the Phase 2 ALTITUDE-AD clinical trial for early Alzheimer's disease, following positive results from its Phase 1 INTERCEPT-AD study. Acumen is also advancing an Enhanced Brain Delivery (EBD™) program, including a collaboration with JCR Pharmaceuticals, and investigating a subcutaneous formulation of sabirnetug.

Recent developments include the appointment of James Doherty as President and Chief Development Officer in February 2024 and George Golumbeski as Chairman of the Board in November 2025. Acumen Pharmaceuticals reported a net loss of $121.3 million for the year ended December 31, 2025, and secured $35.75 million through a private placement in March 2026, which is expected to fund operations into early 2027. The company anticipates reporting topline results for the ALTITUDE-AD trial in late 2026 and an IND filing for a lead EBD program candidate in mid-2027, positioning it as a high-risk, high-reward firm in the Alzheimer's therapeutic space.